Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin

Greco, F. Anthony; Erland, Joan B.; Morrissey, Lisa H.; Burris, Howard A.; Hermann, Róbert; Steis, Ronald G.; Thompson, Dana S.; Gray, James R.; Hainsworth, John D.

doi:10.1023/a:1008369812295

Cited by 103 publications

(75 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The primary efficacy endpoint for this trial was survival; secondary endpoints included the objective response rate and progression-free survival duration. Standard firstline therapy with paclitaxel and carboplatin produces response rates of approximately 30%, and median survival time of approximately 9 months in patients with CUP [1][2][3][4]. In evaluating this new regimen, a higher proportion of patients alive at 9 months, 70% with the investigational combination versus 50% (expected with paclitaxel and carboplatin alone), was considered to be a result supporting further development of this regimen.…”

Section: Statistical Considerationsmentioning

confidence: 99%

See 1 more Smart Citation

Paclitaxel/Carboplatin plus Bevacizumab/Erlotinib in the First-Line Treatment of Patients with Carcinoma of Unknown Primary Site

et al. 2009

View full text Add to dashboard Cite

Introduction. This phase II trial evaluated the efficacy and toxicity of the combination of paclitaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with carcinoma of unknown primary site (CUP).Methods. Patients with previously untreated CUP (adenocarcinoma, poorly differentiated carcinoma, poorly differentiated squamous carcinoma) without clinical or pathologic characteristics of a well-defined treatable subset were eligible. All patients received paclitaxel, carboplatin, bevacizumab, and erlotinib. Treatment cycles were repeated at 21-day intervals. After four cycles, paclitaxel and carboplatin were discontinued; bevacizumab-erlotinib treatment was continued until tumor progression. Patients were initially evaluated for response after completion of two treatment cycles; re-evaluations occurred every 6 weeks thereafter.

show abstract

Section: Statistical Considerationsmentioning

confidence: 99%

“…Empiric chemotherapy with taxane-platinum regimens is widely used for these patients. However, these regimens are only moderately effective, producing response rates of 30%-40%, with 1-and 2-year survival rates of approximately 40% and 20%, respectively [1][2][3][4].…”

Section: Introductionmentioning

confidence: 99%

Paclitaxel/Carboplatin plus Bevacizumab/Erlotinib in the First-Line Treatment of Patients with Carcinoma of Unknown Primary Site

et al. 2009

View full text Add to dashboard Cite

show abstract

“…By restricting diagnostic procedures to a minimum, and with an early start of chemotherapy, median survival has improved from 3 -6 months of the past (Altman and Cadman, 1986;Alberts et al, 1989) to around 1 year in recently reported series (Briasoulis et al, 2000;Greco et al, 2000a).…”

mentioning

confidence: 99%

Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site

et al. 2004

View full text Add to dashboard Cite

The aim of this study was to assess the activity and toxicity of a platinum-based treatment on a group of patients with unknown primary tumours (UPTs). Patients with a diagnosis of UPT underwent a standard diagnostic procedure. Treatment was started within 2 weeks from diagnosis and consisted of carboplatin 400 mg m À2 day 1, doxorubicin 50 mg m À2 day 1, etoposide 100 mg m À2 days 1 -3, every 21 days. Response was evaluated after three courses and treatment continued in case of objective response (OR) or symptom control. A total of 102 patients were eligible. The median age was 59 years, sex male/female 54/48, histology was mainly adenocarcinoma or poorly differentiated carcinoma. Nodes, bone, liver and lung were the most frequently involved sites. In all, 79 patients received at least three courses of treatment; 26 patients received six courses or more. Six complete responses and 21 partial responses were observed, for a total of 27 of 102 ORs or 26.5% (95% confidence interval 18.2 -36.1%). The median survival was 9 months and median progression-free survival was 4 months. Toxicity was moderate to severe, with 57.8% of patients experiencing grade III -IV haematological toxicity, mainly leucopenia. The regimen employed has shown activity in tumours of unknown primary site, but was associated with significant toxicity. Such toxicity may be considered unjustified, given the large proportion of patients with tumours not likely to respond. Efforts should therefore be addressed to identify predictors of response to chemotherapy, thus limiting aggressive treatment to those patients who could benefit from it.

show abstract

“…25 Hopefully, these reports will be the first step toward new progress in the management of patients with CUPs. 12 ViAM 57 30 7 De Campos et al 13 VACy 40 8 4 Hainsworth et al 14 PECa 53 47 13 Lofts et al 15 FcC 44 27 4 Parnis et al 16 FcEpC 43 19 6 Greco et al 17 DC …”

Section: Discussionmentioning

confidence: 99%

Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site

Culine

Fabbro

Ychou

et al. 2002

Cancer

View full text Add to dashboard Cite

BACKGROUNDBecause carcinomas of unknown primary origin are highly malignant tumors with a bad prognosis (median survival, 6–12 months) and no current optimal therapy, the authors designed a prospective dose‐dense chemotherapy regimen with the objective of improving the results observed in patients who receive conventional treatment.METHODSEighty‐two patients received alternative bimonthly cycles of doxorubicin 50 mg/m2 with cyclophosphamide 1000 mg/m2 (AC) and etoposide 300 mg/m2 with cisplatin 100 mg/m2 (EP). Cycles were given at 2‐week intervals with granulocyte‐macrophage–stimulating factor support (5 μg/kg per day) from Day 4 to Day 10. Patients without measurable lesions were included, because the major end point was survival.RESULTSThe median number of alternative cycles of AC and EP was 4 cycles (range, 1–12 cycles). An objective response was observed in 24 of 62 patients (39%; 95% confidence interval, 30–48%) with measurable lesions, including 6 patients who achieved a complete response. Among 20 patients with nonmeasurable disease, 9 patients (45%) had no evidence of progressive disease at the end of chemotherapy. The overall median survival of 82 patients was 10 months, with 5 patients surviving clinically disease free at 17 months, 29 months, 45 months, 64 months, and 70 months after the end of treatment. Myelosuppression was the most common toxicity. Two toxic deaths occurred.CONCLUSIONSUsing these doses and schedules, a dose‐dense chemotherapy regimen did not appear to improve the outcome of patients with carcinoma of unknown primary site. Alternative studies dealing with news drugs will be required. Cancer 2002;94:840–6. © 2002 American Cancer Society.DOI 10.1002/cncr.10264

show abstract

Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin

Cited by 103 publications

References 8 publications

Paclitaxel/Carboplatin plus Bevacizumab/Erlotinib in the First-Line Treatment of Patients with Carcinoma of Unknown Primary Site

Paclitaxel/Carboplatin plus Bevacizumab/Erlotinib in the First-Line Treatment of Patients with Carcinoma of Unknown Primary Site

Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site

Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site

Contact Info

Product

Resources

About